Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.

Investigational new drugs - 1 Apr 2025

Yang Lu, Feng Yanlong, Liu Xuewen, Zhang Qin, Liu Yaqin, Zhang Xing, Li Ping, Chen Dongsheng

Abstract excerpt

Dynein cytoplasmic 2 heavy chain 1 (DYNC2H1) is reported to play a potential role in cancer immunotherapy. However, the association between DYNC2H1 mutation and the clinical benefit of immunotherapy in non-small cell lung cancer (NSCLC) and melanoma remains to be elucidated. We collected data from three public immune checkpoint inhibitor (ICI)-treated NSCLC cohorts (n = 137 in total) and seven ICI-treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cytoplasmic Dyneins

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Melanoma

Share to Prognosis

Source

Identifiers

PMID: 39934438
DOI: 10.1007/s10637-024-01495-3

Genes

DYNC2H1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.PMID 39934438Read ↗

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung CancerSemantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.Semantic proximity Read ↗

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.Semantic proximity Read ↗

PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.Semantic proximity Read ↗

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.Semantic proximity Read ↗

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung AdenocarcinomaSemantic proximity Read ↗

PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.Semantic proximity Read ↗

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.Semantic proximity Read ↗

Hippo Signaling Pathway Regulates Cancer Cell–Intrinsic MHC-II ExpressionSemantic proximity Read ↗

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.